Reference Detail

Ref Type

Abstract

PMID

Authors

Bryan D. Smith; Subha Vogeti; Timothy M. Caldwell; Hanumaiah Telikepalli; Yu Mi Ahn; Gada Al-Ani; Stacie L. Bulfer; Andrew Greenwood; Cale L. Heiniger; Joshua W. Large; Cynthia B. Leary; Wei-Ping Lu; Kylie Luther; William C. Patt; Max D. Petty; Yeni K. Romero; Forrest A. Stanley; Kristen L. Stoltz; Daniel C. Tanner; Sihyung Yang; Yu Zhan; Bertrand Le Bourdonnec; Daniel L. Flynn

Title

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Journal	Vol	Issue	Date	Pages	Journal Short Title
Cancer Research	83	7_Supplement	April 1, 2023

URL

https://aacrjournals.org/cancerres/article/83/7_Supplement/4033/724685/Abstract-4033-Pan-exon-mutant-KIT-inhibitor-DCC

Abstract Text

Introduction: Gastrointestinal stromal tumors (GISTs) are typically driven by primary mutations in KIT exons 9 or 11. Heterogeneous drug-resistant secondary mutations arise in patients treated with FDA approved KIT inhibitors, including imatinib and sunitinib. Drug resistant secondary mutations are found at multiple regions in the ATP pocket (encoded by exons 13 and 14) or activation switch (encoded by exons 17 and 18) of KIT kinase. In addition, multiple drug-resistant clones can arise within a tumor or in metastatic tumor sites. An inhibitor that can broadly and potently inhibit the spectrum of KIT mutations is highly sought. Ripretinib has been FDA approved as a 4th line treatment for GIST and has broad activity against KIT mutations, including clinical potency in patients with mutations in KIT exons 11, 17, or 18. DCC-3009 was designed as a next generation KIT inhibitor that broadly and potently inhibits primary KIT mutations in exons 9 and 11 and secondary drug-resistant mutations across exons 13, 14, 17, and 18. DCC-3009 is a potent and selective inhibitor in enzyme and cell-based assays, and has demonstrated efficacy in xenograft models driven by drug resistant KIT mutations. Methods: DCC-3009 was tested for inhibition of KIT mutants using standard enzyme and cell-based assays. Levels of phosphorylated KIT were determined by Western blot or ELISA. Proliferation was measured using the fluorescent dye resazurin. KIT mutant xenograft or patient-derived xenograft models were performed at Crown Biosciences or Labcorp, AAALAC accredited facilities, with the approval of Animal Care and Use Committees. Results: In BaF3 cells transfected with KIT mutants, DCC-3009 was shown to potently inhibit the spectrum of known primary and secondary drug-resistant mutations in GIST. The pan-mutant KIT profile of DCC-3009 was shown in vitro to be superior to 2nd and 3rd line standard of care therapies sunitinib and regorafenib. DCC-3009 was selective for KIT when screened against a large panel of kinases. DCC-3009 has optimized pharmaceutical properties for oral administration. In pharmacokinetic/pharmacodynamic studies DCC-3009 achieved sufficient free drug levels to significantly inhibit drug-resistant KIT mutants for 12 hr post dose. In xenograft studies, treatment with DCC-3009 twice daily led to tumor regression in drug-resistant models with KIT exon 9/13, 11/13 or 11/17 mutations. Conclusions: DCC-3009 is a pan-exon mutant KIT inhibitor exhibiting high potency in KIT mutants in pre-clinical models spanning exons 9, 11, 13, 14, 17 and 18. In vivo, DCC-3009 exhibited efficacy in drug-resistant models with KIT exon 9/13, 11/13 or 11/17 mutations. Based on this profile, DCC-3009 has entered formal preclinical development.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
DCC-3009	DCC-3009	2	0

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
DCC-3009		DCC3009\|DCC 3009	KIT Inhibitor 57	DCC-3009 is a KIT inhibitor with activity against exon 9 and 11 mutations, as well as mutations in exons 13, 14, 17, and 18, potentially resulting in decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 4033).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT exon11 KIT exon13	gastrointestinal stromal tumor	predicted - sensitive	DCC-3009	Preclinical	Actionable	In a preclinical study, DCC-3009 induced tumor regression in a xenograft model of gastrointestinal stromal tumor harboring KIT exon 11 and exon 13 mutations (Cancer Res (2023) 83 (7_Supplement): 4033).	detail...
KIT exon11 KIT exon17	gastrointestinal stromal tumor	predicted - sensitive	DCC-3009	Preclinical	Actionable	In a preclinical study, DCC-3009 induced tumor regression in a xenograft model of gastrointestinal stromal tumor harboring KIT exon 11 and exon 17 mutations (Cancer Res (2023) 83 (7_Supplement): 4033).	detail...